3. Gavi and Meningococcal Vaccines
β’ Meningococcal A Conjugate Vaccine (i.e., MenAfrivac) rollout
began in 2010 with Gavi support, with 26 countries in the African
meningitis belt eligible for Gavi funding support
β’ Routine immunization
β’ Preventive campaigns targeting individuals 1-29 years of age
β’ No meningococcal A cases identified in belt since 2018
β’ In 2018, non-A outbreaks prompted Gavi Board to authorize
multivalent meningococcal conjugate vaccine, contingent on
β’ Availabilityof a licensed product
β’ Outcomes of regulatoryand technical review processes
(including WHO PQ and SAGE recommendations)
β’ Meeting of specific vaccinecost targets
3